Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.15362
Abstract: Acalabrutinib, a selective Bruton tyrosine kinase inhibitor, is approved for the treatment of mantle cell lymphoma and chronic lymphocytic leukaemia. Many critically ill patients are unable to swallow and need oral medications to be delivered… read more here.
Keywords: proton pump; via nasogastric; nasogastric tube; delivered via ... See more keywords
Pharmacokinetic Profile of Prolonged-Release Tacrolimus When Administered via Nasogastric Tube in De Novo Liver Transplantation: A Sub-Study of the DIAMOND Trial
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Transplantation"
DOI: 10.12659/aot.909693
Abstract: Background For patients unable to swallow during the immediate post-transplant period, immunosuppressant therapy may be initiated by administering prolonged-release tacrolimus as a suspension via a nasogastric tube. Material/Methods In this sub-study of the DIAMOND randomized… read more here.
Keywords: via nasogastric; release tacrolimus; day; tacrolimus ... See more keywords